ES2190246T3 - Nuevos compuestos de tiazolopirimidina. - Google Patents

Nuevos compuestos de tiazolopirimidina.

Info

Publication number
ES2190246T3
ES2190246T3 ES99943554T ES99943554T ES2190246T3 ES 2190246 T3 ES2190246 T3 ES 2190246T3 ES 99943554 T ES99943554 T ES 99943554T ES 99943554 T ES99943554 T ES 99943554T ES 2190246 T3 ES2190246 T3 ES 2190246T3
Authority
ES
Spain
Prior art keywords
compounds
thiazolopirimidine
new
therapy
processes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99943554T
Other languages
English (en)
Inventor
Rupert Austin
Andrew Baxter
Roger Bonnert
Fraser Hunt
Elizabeth Kinchin
Paul Willis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2190246T3 publication Critical patent/ES2190246T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un compuesto de fórmula general **(Fórmula)** en la que R1 representa un átomo de hidrógeno, o un grupo -NR3R4; R3 y R4 representan cada uno independientemente un átomo de hidrógeno, o un grupo 4-piperidinilo, cicloalquilo C3-C6 o alquilo C1-C8, los cuales dos últimos grupos pueden estar opcionalmente sustituidos por uno o más grupos sustituyentes seleccionados independientemente entre átomos de halógeno y grupos -NR5R6, -CONR5R6, -OR7, -COOR7, -NR8COR9, -SR10, SO2R10, -SO2NR5R6, -NR8SO2R9, morfolinilo, alquilo C1-C4, cicloalquilo C3-C6, tetrahidrofuranilo y arilo, en que un grupo sustituyente arilo puede ser un grupo fenilo, naftilo, tienilo, piridinilo, imidazolilo o indolilo, cada uno de los cuales puede estar opcionalmente sustituido por uno o más sustituyentes seleccionados independientemente entre átomos de halógeno y grupos ciano, nitro, -NR5R6, -CONR5R6, -OR7, -NR8COR9, -SO2NR5R6, -NR8SO2R9, alquilo C1-C6 y trifluorometilo, o R3 y R4 junto con el átomo de nitrógeno al cual están unidos forman un sistema anular heterocíclico saturado de 4 a 7 miembros, el cual sistema anular puede estar opcionalmente sustituido por uno o más grupos sustituyentes seleccionados independientemente entre grupos **(Fórmula)** -NR5R6, -CONR5R6, -OR7, -COOR10, -NR8COR9, y alquilo C1-C6 opcionalmente sustituido por uno o más sustituyentes seleccionados independientemente entre átomos de halógeno y grupos -NR11R12 y -OR7; X representa un grupo -OH o -NR13R14; R13 y R14 representan cada uno independientemente un átomo de hidrógeno, un grupo 4-piperidinilo opcionalmente sustituido por un grupo sustituyente alquilfenilo C1-C4, o un grupo carbocíclico C3-C7, alquilo C1-C8, alquenilo C2-C6 o alquinilo C2-C6, los cuales cuatro últimos grupos pueden estar opcionalmente sustituidos por uno o más grupos sustituyentes seleccionados independientemente entre átomos de halógeno y grupos -NR5R6, -CONR5R6, -OR7, -COOR7, -NR8COR9, -SR10, SO2R10, -SO2NR5R6, -NR8SO2R9, morfolinilo, alquilo C1-C4, cicloalquilo C3-C6 y arilo, en que un grupo sustituyente arilo puede ser un grupo fenilo, naftilo, tienilo, piridinilo, imidazolilo o indolilo, cada uno de los cuales puede estar opcionalmente sustituido por uno o más sustituyentes seleccionados independientemente entre átomos de halógeno y grupos ciano, nitro, -NR5R6, -CONR5R6, -OR7, -NR8COR9, -SO2NR5R6, -NR8SO2R9, alquilo C1-C6 y trifluorometilo, o R13 y R14 junto con el átomo de nitrógeno al cual están unidos forman un sistema anular heterocíclico saturado de 4 a 7 miembros, el cual sistema anular puede estar opcionalmente sustituido por uno o más grupos sustituyentes seleccionados independientemente entre -NR5R6, -CONR5R6, -OR7, -COOR7, -NR8COR9, y alquilo C1-C6 opcionalmente sustituido por uno o más sustituyentes seleccionados independientemente entre átomos de halógeno y grupos fenilo, -NR11R12 y -OR7; R2 representa un grupo alquilo C1-C6 o alquenilo C2-C6 opcionalmente sustituido por un grupo fenilo o fenoxi, en el que el grupo fenilo o fenoxi puede estar él mismo opcionalmente sustituido por uno o más sustituyentes seleccionados independientemente entre átomos de halógeno y grupos nitro, alquilo C1-C6, trifluorometilo, -OR7, -C(O)R7, -SR10, -NR15R16 y fenilo; R5 y R6 representan cada uno independientemente un átomo de hidrógeno o un grupo alquilo C1-C6 o fenilo, cada uno de los cuales puede estar opcionalmente sustituido por uno o más grupos sustituyentes seleccionados independientemente entre átomos de halógeno, fenilo -OR17 y -NR15R16, o R5 y R6 junto con el átomo de nitrógeno al cual están unidos forman un sistema anular heterocíclico saturado de 4 a 7 miembros que comprende opcionalmente un heteroátomo adicional seleccionado entre átomos de oxígeno y nitrógeno, el cual sistema anular puede estar opcionalmente sustituido por uno o más grupos sustituyentes seleccionados independientemente entre grupos fenilo, -OR17, -COOR17, -NR15R16, -CONR15R16, -NR15COR16, -SONR15R16, y alquilo C1-C6 opcionalmente sustituido por uno o más sustituyentes seleccionados independientemente entre átomos de halógeno y grupos -NR15R16, y -OR17; R7 y R9 representan cada uno independientemente un átomo de hidrógeno o un grupo alquilo C1-C6 o fenilo, cada uno de los cuales puede estar opcionalmente sustituido por uno o ma¿s grupos sustituyentes seleccionados independientemente entre átomos de halógeno, fenilo, -OR17 y -NR15R16; y cada uno de los R8, R10, R11, R12, R15, R16 y R17representan independientemente un átomo de hidrógeno o un grupo alquilo C1-C6 o fenilo; con la condición de que cuando R1 y X representan ambos -NH2, entonces R2 no represente un grupo metilo; o una sal o solvato del mismo farmacéuticamente aceptable.
ES99943554T 1998-08-13 1999-08-03 Nuevos compuestos de tiazolopirimidina. Expired - Lifetime ES2190246T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9802729A SE9802729D0 (sv) 1998-08-13 1998-08-13 Novel Compounds

Publications (1)

Publication Number Publication Date
ES2190246T3 true ES2190246T3 (es) 2003-07-16

Family

ID=20412248

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99943554T Expired - Lifetime ES2190246T3 (es) 1998-08-13 1999-08-03 Nuevos compuestos de tiazolopirimidina.

Country Status (12)

Country Link
US (1) US6806273B1 (es)
EP (1) EP1104425B1 (es)
JP (2) JP4612189B2 (es)
AT (1) ATE231872T1 (es)
AU (1) AU768004B2 (es)
CA (1) CA2338600C (es)
DE (1) DE69905170T2 (es)
DK (1) DK1104425T3 (es)
ES (1) ES2190246T3 (es)
NZ (1) NZ509457A (es)
SE (1) SE9802729D0 (es)
WO (1) WO2000009511A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903544D0 (sv) * 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359078A (en) * 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359081A (en) * 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
ATE255584T1 (de) * 2000-02-11 2003-12-15 Astrazeneca Ab Pyrimidinverbindungen und ihre verwendung als modulatoren der chemokin-rezeptor-aktivität
GB2359551A (en) * 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
BR0112603A (pt) * 2000-07-18 2004-08-24 Smithkline Beecham Corp Uso de antagonistas receptores de il-8 no tratamento de infecções por vìrus
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
SE0101082D0 (sv) 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
SE0101322D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
SE0102716D0 (sv) * 2001-08-14 2001-08-14 Astrazeneca Ab Novel compounds
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
WO2004013141A1 (en) 2002-08-06 2004-02-12 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (tek) activity
WO2004018435A1 (en) * 2002-08-24 2004-03-04 Astrazeneca Ab Pyrimidine derivatives as modulators of chemokine receptor activity
GB0221829D0 (en) * 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
KR20060120014A (ko) * 2003-10-07 2006-11-24 아스트라제네카 아베 케모킨, 특히 ｃｘ3ｃｒ1 수용체 길항제로서 유용한 신규한2-치환된 4-아미노-티아졸로[4,5-ｄ]피리미딘
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
PT1809624E (pt) 2004-08-28 2014-01-14 Astrazeneca Ab Derivados de pirimidina sulfonamida como moduladores do recetor de quimiocina
WO2006046739A1 (ja) 2004-10-29 2006-05-04 Eisai R & D Management Co., Ltd. 炎症性疾患治療剤
EP1844054A2 (en) * 2004-12-17 2007-10-17 AstraZeneca AB Thiazolopyrimidine compounds for the modulation of chemokine receptor activity
AR053347A1 (es) * 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
UA90707C2 (en) * 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
TW200820973A (en) 2006-09-29 2008-05-16 Astrazeneca Ab Novel compounds 480
EP2069365A4 (en) * 2006-09-29 2011-11-02 Astrazeneca Ab NOVEL [1, 3] THIAZOLO [4,5-D] PYRIMIDIN-2 (3H) -AMINE 5,7-DISUBSTITUTED DERIVATIVES AND THEIR USE IN THERAPY
WO2008094662A2 (en) 2007-02-01 2008-08-07 Interdigital Technology Corporation Method and apparatus for supporting rlc re-segmentation
CN101959889A (zh) * 2008-02-26 2011-01-26 诺瓦提斯公司 作为cxcr2抑制剂的杂环化合物
JP5756096B2 (ja) 2009-06-12 2015-07-29 ソックプラ−シアンセ エ ジェニー エス．ウ．セ． グアニンリボスイッチ結合化合物及び抗生物質としてのその使用
JO3437B1 (ar) 2009-10-30 2019-10-20 Esai R & D Man Co Ltd أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
CN106279211B (zh) * 2015-06-03 2020-09-15 北京大学 一种噻唑并嘧啶酮化合物及其制备方法和应用
GB201807898D0 (en) * 2018-05-15 2018-06-27 Kancera Ab New processes and products with increased chiral purity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB713652A (en) * 1951-06-04 1954-08-18 Wellcome Found Improvements in or relating to heterocyclic compounds and their manufacture
BE543978A (es) * 1955-01-03
US5202328A (en) * 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
JP2002510695A (ja) * 1998-04-03 2002-04-09 デュポン ファーマシューティカルズ カンパニー 副腎皮質刺激ホルモン放出因子（ＣＲＦ）拮抗剤としてのチアゾロ［４，５−ｄ］ピリミジンおよびピリジン

Also Published As

Publication number Publication date
WO2000009511A1 (en) 2000-02-24
AU768004B2 (en) 2003-11-27
AU5662599A (en) 2000-03-06
EP1104425B1 (en) 2003-01-29
NZ509457A (en) 2002-07-26
EP1104425A1 (en) 2001-06-06
US6806273B1 (en) 2004-10-19
CA2338600C (en) 2008-01-08
DK1104425T3 (da) 2003-06-23
SE9802729D0 (sv) 1998-08-13
DE69905170T2 (de) 2004-01-15
ATE231872T1 (de) 2003-02-15
JP4612189B2 (ja) 2011-01-12
JP2002522544A (ja) 2002-07-23
CA2338600A1 (en) 2000-02-24
JP2010168405A (ja) 2010-08-05
DE69905170D1 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
ES2190246T3 (es) Nuevos compuestos de tiazolopirimidina.
BR9916896A (pt) Diaril aminas substituìdas com 1-heterociclo
SE9704546D0 (sv) Novel compounds
PT960107E (pt) Compostos de paclitaxel 6-tio-substituidos
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
TR200100054T2 (tr) Paroksetin metansülfonat
EE200000468A (et) Ühendid, nende kasutamine ja farmatseutiline kompositsioon
TR200001218T2 (tr) İkameli karboksamidotiazoller, bunların üretimi ve bunları içeren farmasötik bileşimler.
SE9704545D0 (sv) Novel compounds
SE9704544D0 (sv) Novel compounds
TR200001203T2 (tr) Yeni birleşik maddeler
ID23374A (id) Halogenopirimidin
TR200000152T2 (tr) Yeni bileşikler.
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
AR016981A2 (es) Polipeptidos sinteticos
YU13301A (sh) Muskarinski agonisti i antagonisti
SE9802937D0 (sv) Novel compounds
SE0102716D0 (sv) Novel compounds
SE9801494D0 (sv) Novel use
MY127474A (en) Naphthyl compounds, intermediates, compositions, and methods of use
ATE28188T1 (de) Antikonvulsive mittel.
NO20005548L (no) Mykobakterieinhibitorer
ATE57526T1 (de) P-acylaminobenzamide.
PT1011329E (pt) Paclitaxeis de 7-metiltio-oxometilo e 7-metiltiodioxometilo
NO20021429L (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner